F3F
VC Fund
F3F is a VC fund focused on Biotechnology and Medical Device. F3F
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries F3F invests in
Stages F3F invests in
Countries F3F invests in
Round sizes
Round size
- Series A
- $232k–$9.2M
- Series B
- $567k–$14M
Investment Focus
Industry
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
- Hardware 1 (13%)
- Hospital 1 (13%)
- Software 1 (13%)
Stage
- Series A 3 (38%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Venture - Series Unknown 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $14.2M / Series B / Feb 13, 2025 | ||
| WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper. | $17.6M / Series C / Oct 01, 2020 | ||
| Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $9.2M / Series A / Sep 25, 2019 | ||
| early diagnosis and monitoring of neurological and neurodegenerative diseases in liquid biopsies, based on miRNA from microglial microvesicles. | $567.1K / Series B / Dec 04, 2018 | ||
| early diagnosis and monitoring of neurological and neurodegenerative diseases in liquid biopsies, based on miRNA from microglial microvesicles. | $231.8K / Series A / Mar 01, 2017 | ||
| early diagnosis and monitoring of neurological and neurodegenerative diseases in liquid biopsies, based on miRNA from microglial microvesicles. | $447.8K / Seed / Sep 01, 2016 | ||
| Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $1.9M / Venture - Series Unknown / Jun 14, 2016 | ||
| WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper. | $3.4M / Series A / Jun 09, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does F3F invest in?
F3F invests primarily in Biotechnology, Medical Device and Hardware startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is F3F's check size?
F3F typically joins rounds of $232k–$9.2M at Series A and $567k–$14M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds F3F participates in.
When did F3F last invest?
The most recent investment recorded for F3F closed in Feb 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
